L Weng1, D Ziliak1, H K Im2, E R Gamazon1, S Philips3, A T Nguyen3, Z Desta3, T C Skaar3, D A Flockhart3, R S Huang4. 1. Department of Medicine. 2. Health Studies, University of Chicago, Chicago. 3. Department of Medicine, Division of Clinical Pharmacology, School of Medicine, Indiana University, Indianapolis, USA. 4. Department of Medicine. Electronic address: rhuang@medicine.bsd.uchicago.edu.
Abstract
BACKGROUND: Beyond estrogen receptor (ER), there are no validated predictors for tamoxifen (TAM) efficacy and toxicity. We utilized a genome-wide cell-based model to comprehensively evaluate genetic variants for their contribution to cellular sensitivity to TAM. DESIGN: Our discovery model incorporates multidimensional datasets, including genome-wide genotype, gene expression, and endoxifen-induced cellular growth inhibition in the International HapMap lymphoblastoid cell lines (LCLs). Genome-wide findings were further evaluated in NCI60 cancer cell lines. Gene knock-down experiments were performed in four breast cancer cell lines. Genetic variants identified in the cell-based model were examined in 245 Caucasian breast cancer patients who underwent TAM treatment. RESULTS: We identified seven novel single-nucleotide polymorphisms (SNPs) associated with endoxifen sensitivity through the expression of 10 genes using the genome-wide integrative analysis. All 10 genes identified in LCLs were associated with TAM sensitivity in NCI60 cancer cell lines, including USP7. USP7 knock-down resulted in increasing resistance to TAM in four breast cancer cell lines tested, which is consistent with the finding in LCLs and in the NCI60 cells. Furthermore, we identified SNPs that were associated with TAM-induced toxicities in breast cancer patients, after adjusting for other clinical factors. CONCLUSION: Our work demonstrates the utility of a cell-based model in genome-wide identification of pharmacogenomic markers.
BACKGROUND: Beyond estrogen receptor (ER), there are no validated predictors for tamoxifen (TAM) efficacy and toxicity. We utilized a genome-wide cell-based model to comprehensively evaluate genetic variants for their contribution to cellular sensitivity to TAM. DESIGN: Our discovery model incorporates multidimensional datasets, including genome-wide genotype, gene expression, and endoxifen-induced cellular growth inhibition in the International HapMap lymphoblastoid cell lines (LCLs). Genome-wide findings were further evaluated in NCI60 cancer cell lines. Gene knock-down experiments were performed in four breast cancer cell lines. Genetic variants identified in the cell-based model were examined in 245 Caucasian breast cancerpatients who underwent TAM treatment. RESULTS: We identified seven novel single-nucleotide polymorphisms (SNPs) associated with endoxifen sensitivity through the expression of 10 genes using the genome-wide integrative analysis. All 10 genes identified in LCLs were associated with TAM sensitivity in NCI60 cancer cell lines, including USP7. USP7 knock-down resulted in increasing resistance to TAM in four breast cancer cell lines tested, which is consistent with the finding in LCLs and in the NCI60 cells. Furthermore, we identified SNPs that were associated with TAM-induced toxicities in breast cancerpatients, after adjusting for other clinical factors. CONCLUSION: Our work demonstrates the utility of a cell-based model in genome-wide identification of pharmacogenomic markers.
Entities:
Keywords:
HapMap; SNP; gene expression; genome-wide association study; tamoxifen
Authors: Zaineb R Abdul Razak; Robert J Varkonyi; Michelle Kulp-McEliece; Corrado Caslini; Joseph R Testa; Maureen E Murphy; Dominique Broccoli Journal: Mol Cell Biol Date: 2004-07 Impact factor: 4.272
Authors: Ann M Moyer; Vera J Suman; Richard M Weinshilboum; Rajeswari Avula; John L Black; Stephanie L Safgren; Mary J Kuffel; Matthew M Ames; James N Ingle; Matthew P Goetz Journal: Pharmacogenomics Date: 2011-10-03 Impact factor: 2.533
Authors: Ron H N van Schaik; Marleen Kok; Fred C G J Sweep; Martin van Vliet; Marianne van Fessem; Marion E Meijer-van Gelder; Caroline Seynaeve; Jan Lindemans; Jelle Wesseling; Laura J Van 't Veer; Paul N Span; Hanneke van Laarhoven; Stefan Sleijfer; John A Foekens; Sabine C Linn; Els M J J Berns Journal: Pharmacogenomics Date: 2011-08-10 Impact factor: 2.533
Authors: Yan Jin; Zeruesenay Desta; Vered Stearns; Bryan Ward; Herbert Ho; Kyung-Hoon Lee; Todd Skaar; Anna Maria Storniolo; Lang Li; Adjei Araba; Rebecca Blanchard; Anne Nguyen; Lynda Ullmer; Jill Hayden; Suzanne Lemler; Richard M Weinshilboum; James M Rae; Daniel F Hayes; David A Flockhart Journal: J Natl Cancer Inst Date: 2005-01-05 Impact factor: 13.506
Authors: Rong Stephanie Huang; Emily O Kistner; Wasim K Bleibel; Sunita J Shukla; M Eileen Dolan Journal: Mol Cancer Ther Date: 2007-01 Impact factor: 6.261
Authors: Barbara E Stranger; Alexandra C Nica; Matthew S Forrest; Antigone Dimas; Christine P Bird; Claude Beazley; Catherine E Ingle; Mark Dunning; Paul Flicek; Daphne Koller; Stephen Montgomery; Simon Tavaré; Panos Deloukas; Emmanouil T Dermitzakis Journal: Nat Genet Date: 2007-09-16 Impact factor: 38.330
Authors: D P Patel; W O Brant; J B Myers; A P Presson; E B Johnstone; J A Dorais; K I Aston; D T Carrell; J M Hotaling Journal: Int J Impot Res Date: 2015-08-20 Impact factor: 2.896